Microtubule stabilizing agents: Their molecular signaling consequences and the potential for enhancement by drug combination

被引:76
作者
Bergstralh, Daniel T.
Ting, Jenny P. -Y.
机构
[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA
关键词
taxanes; microtubules; spindle checkpoint; MEK; NF-kappa B; Akt; COX-2;
D O I
10.1016/j.ctrv.2006.01.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Microtubule stabilization by chemotherapy is a powerful weapon in the war against cancer. Disruption of the mitotic spindle activates a number of signaling pathways, with consequences that may protect the cell or lead to its death via apoptosis. Taxol, the first microtubule stabilizing drug to be identified, has been utilized successfully in the treatment of solid tumors for two decades. Several features, however, make this drug less than ideal, and the search for next generation stabilizing drugs with increased efficacy has been intense and fruitful. Microtubule stabilizing agents (MSAs), including the taxanes, the epothilones, discodermolide, laulimalide, and eleutherobin, form an important and expanding family of chemotherapeutic agents. A strong understanding of their molecular signaling consequences is essential to their value, particularly in regard to their potential for combinatorial chemotherapy - the use of multiple agents to enhance the efficacy of cancer treatment. Here we present a critical review of research on the signaling mechanisms induced by MSAs, their relevance to apoptosis, and their potential for exploitation by combinatorial therapy. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:166 / 179
页数:14
相关论文
共 197 条
[1]  
Abrieu A, 2001, J CELL SCI, V114, P257
[2]   Chromosomal passengers and the (aurora) ABCs of mitosis [J].
Adams, RR ;
Carmena, M ;
Earnshaw, WC .
TRENDS IN CELL BIOLOGY, 2001, 11 (02) :49-54
[3]   Cl-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK) [J].
Allen, LF ;
Sebolt-Leopold, J ;
Meyer, MB .
SEMINARS IN ONCOLOGY, 2003, 30 (05) :105-116
[4]   Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer [J].
Altorki, NK ;
Port, JL ;
Zhang, F ;
Golijanin, D ;
Thaler, HT ;
Duffield-Lillico, AJ ;
Subbaramaiah, K ;
Dannenberg, AJ .
CLINICAL CANCER RESEARCH, 2005, 11 (11) :4191-4197
[5]   Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer [J].
Altorki, NK ;
Keresztes, RS ;
Port, JL ;
Libby, MD ;
Korst, RJ ;
Flieder, DB ;
Ferrara, CA ;
Yankelevitz, DF ;
Subbaramaiah, K ;
Pasmantier, MW ;
Dannenberg, AJ .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2645-2650
[6]   A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J].
Ambrosini, G ;
Adida, C ;
Altieri, DC .
NATURE MEDICINE, 1997, 3 (08) :917-921
[7]   AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol [J].
Anand, S ;
Penrhyn-Lowe, S ;
Venkitaraman, AR .
CANCER CELL, 2003, 3 (01) :51-62
[8]   mTOR: a protein kinase switching between life and death [J].
Asnaghi, L ;
Bruno, P ;
Priulla, M ;
Nicolin, A .
PHARMACOLOGICAL RESEARCH, 2004, 50 (06) :545-549
[9]   Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase i study [J].
Athanasiadis, A ;
Roussos, G ;
Papakostoulis, T ;
Athanasiadou, DC ;
Stathopoulos, GP .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (06) :653-658
[10]   The NF-kappa B and I kappa B proteins: New discoveries and insights [J].
Baldwin, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683